Telomere Therapeutics strives to provide patients suffering of devastating fibrotic disease through the development of a first curative and disease modifying treatment through its first-in-class gene therapy.

DanausGT is a born-gloabl start-up company with offices from Asia to Europe developing state of the art cell and gene therapies dedicated to providing patients with curative treatments to devastating disease, entailing the use of state of the art CRISPR-AAV gene editing technology for efficient & holistic whole-gene correction.

The Botin Foundation's Science Program aims to globally address national science and technology (S&T) issues, and particularly tackles issues in knowledge and technology transfer, technology development, by promoting the acceleration of translational research in biomedical biotechnology.Michael lead numerous external collaborations with academic and biotech partners, which included large molecule, small molecule and gene therapy programs. During his time at the Botin Foundation, he also gained considerable experience in preclinical research and early development, managing discovery programs across a range of therapeutic areas including neuroscience, oncology, rare diseases and gene therappies.

Cross Road Biotech is a venture capital management firm that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses. To that end, the company selects innovative projects led by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice.CRB Inverbío is based upon the expertise and successful track record in continuous value creation of Cross Road Biotech. CRB Inverbío has a unique competitive advantage: the expertise, analytical capabilities and commitment to succeed of the management team: a key element to build highly successful businesses and maximize the returns to the investors.CRB Inverbío manages Funds and Venture Capital Firms specialized in life sciences. At present the company is launching CRB Bio II, a 60M€ venture capital fund to invest in emerging companies for life sciences, an attractive opportunity to participate in one of the most powerful investment sector of the new economy.

National Cancer Research Centre